Since ACEis and ARBs are found in the medications given to some NCD patients that have hypertension, diabetes, CVD, and CKD, it means that in these patients; the ACE2 activity is increased and may give COVID‐19 an easier access into the cell. Here, ACE2 is linked to COVID-19.